Louis Edward Tamayo Sells 4,117 Shares of Lexeo Therapeutics (NASDAQ:LXEO) Stock

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CFO Louis Edward Tamayo sold 4,117 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $4.91, for a total value of $20,214.47. Following the completion of the sale, the chief financial officer directly owned 92,907 shares of the company’s stock, valued at $456,173.37. The trade was a 4.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Louis Edward Tamayo also recently made the following trade(s):

• On Wednesday, July 1st, Louis Edward Tamayo sold 4,641 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $4.49, for a total value of $20,838.09.

Lexeo Therapeutics Stock Performance

Shares of NASDAQ:LXEO opened at $5.06 on Friday. Lexeo Therapeutics, Inc. has a 52-week low of $3.99 and a 52-week high of $10.99. The business’s 50 day simple moving average is $4.72 and its two-hundred day simple moving average is $5.55. The firm has a market cap of $415.15 million, a P/E ratio of -4.40 and a beta of 1.46.

Lexeo Therapeutics (NASDAQ:LXEO) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.01). On average, equities analysts forecast that Lexeo Therapeutics, Inc. will post -1.18 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. Chardan Capital upgraded shares of Lexeo Therapeutics to a “strong-buy” rating in a report on Tuesday, July 28th. Weiss Ratings upgraded shares of Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th. JPMorgan Chase & Co. decreased their target price on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, June 25th. Finally, Wall Street Zen lowered shares of Lexeo Therapeutics from a “hold” rating to a “strong sell” rating in a report on Saturday, August 15th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Lexeo Therapeutics has an average rating of “Buy” and an average target price of $18.75.

Hedge Funds Weigh In On Lexeo Therapeutics

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. bought a new position in shares of Lexeo Therapeutics during the second quarter valued at about $26,717,000. Montanova Capital LLC boosted its holdings in Lexeo Therapeutics by 410.7% during the second quarter. Montanova Capital LLC now owns 6,384,200 shares of the company’s stock worth $29,718,000 after purchasing an additional 5,134,200 shares during the last quarter. RA Capital Management L.P. bought a new stake in Lexeo Therapeutics in the 4th quarter worth about $49,650,000. Paradigm Biocapital Advisors LP bought a new stake in Lexeo Therapeutics in the 4th quarter worth about $47,299,000. Finally, Balyasny Asset Management L.P. bought a new stake in Lexeo Therapeutics in the 2nd quarter worth about $16,117,000. 60.67% of the stock is owned by hedge funds and other institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.